tiprankstipranks
Madrigal (CH:YDO1)
NASDAQ:YDO1
Switzerland Market
YDO1
Madrigal Pharmaceuticals
RESEARCH TOOLSreports

Madrigal Pharmaceuticals (YDO1) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

YDO1 Analyst Ratings

Strong Buy
9Ratings
Strong Buy
8 Buy
1 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Madrigal
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

YDO1 Stock 12 Month Forecast

Average Price Target

$548.09
Based on 9 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $548.09 with a high forecast of $780.75 and a low forecast of $415.96. The average price target represents a ― change from the last price of ―.
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
Highest Price Target$780.75Average Price Target$548.09Lowest Price Target$415.96
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:YDO1
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF728.91
Buy
―
Reiterated
06/29/26
Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Bank of America Securities Analyst forecast on CH:YDO1
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF445.45→CHF438.97
Hold
―
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL), Moderna (NASDAQ: MRNA) and Ionis Pharmaceuticals (NASDAQ: IONS)
H.C. Wainwright Analyst forecast on CH:YDO1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF502.14
Buy
―
Reiterated
05/28/26
Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data
Truist Financial Analyst forecast on CH:YDO1
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF574.22→CHF415.96
Buy
―
Reiterated
05/26/26
Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)
Barclays Analyst forecast on CH:YDO1
Eliana Merle
Barclays
Barclays
CHF780.75
Buy
―
Assigned
05/08/26
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays
Canaccord Genuity Analyst forecast on CH:YDO1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF475.41→CHF468.12
Buy
―
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $578 from $587 at CanaccordMadrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
Evercore ISI Analyst forecast on CH:YDO1
Michael DiFiore
Evercore ISI
Evercore ISI
CHF528.06→CHF525.63
Buy
―
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
TD Cowen Analyst forecast on CH:YDO1
Ritu Baral
TD Cowen
TD Cowen
CHF521.58
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL) and Pennant Group (NASDAQ: PNTG)
Clear Street Analyst forecast on CH:YDO1
Kaveri Pohlman
Clear Street
Clear Street
CHF431.68→CHF550.73
Buy
―
Reiterated
05/06/26
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Oppenheimer Analyst forecast on CH:YDO1
Jay Olson
Oppenheimer
Oppenheimer
CHF526.44
Buy
―
Reiterated
02/09/26
Citizens JMP Analyst forecast on CH:YDO1
Jonathan Wolleben
Citizens JMP
Citizens JMP
CHF426.82→CHF603.38
Buy
―
Reiterated
01/20/26
Madrigal Pharmaceuticals price target raised to $745 from $527 at CitizensMadrigal Pharmaceuticals price target raised to $745 from $527 at Citizens
Wolfe Research Analyst forecast on CH:YDO1
Andy Chen
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
01/06/26
Madrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe ResearchMadrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
B. Riley Securities Analyst forecast on CH:YDO1
William Wood
B. Riley Securities
B. Riley Securities
CHF453.55→CHF542.63
Buy
―
Reiterated
12/11/25
Madrigal Pharmaceuticals price target raised to $670 from $560 at B. RileyMadrigal Pharmaceuticals price target raised to $670 from $560 at B. Riley
Cantor Fitzgerald Analyst forecast on CH:YDO1
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Upgraded
11/04/25
Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor FitzgeraldMadrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
Leerink Partners Analyst forecast on CH:YDO1
Thomas Smith
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
08/19/25
Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra's European Market Breakthrough
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:YDO1
Yasmeen Rahimi
Piper Sandler
Piper Sandler
CHF728.91
Buy
―
Reiterated
06/29/26
Piper Sandler Remains a Buy on Madrigal Pharmaceuticals (MDGL)
Bank of America Securities Analyst forecast on CH:YDO1
Jason Zemansky
Bank of America Securities
Bank of America Securities
CHF445.45→CHF438.97
Hold
―
Reiterated
06/11/26
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL), Moderna (NASDAQ: MRNA) and Ionis Pharmaceuticals (NASDAQ: IONS)
H.C. Wainwright Analyst forecast on CH:YDO1
Andrew Fein
H.C. Wainwright
H.C. Wainwright
CHF502.14
Buy
―
Reiterated
05/28/26
Analyst Reiterates Buy on Madrigal Pharmaceuticals, Maintains $620 Price Target on Strengthened Rezdiffra MASH and Cardiometabolic Data
Truist Financial Analyst forecast on CH:YDO1
Srikripa Devarakonda
Truist Financial
Truist Financial
CHF574.22→CHF415.96
Buy
―
Reiterated
05/26/26
Analysts Are Bullish on Top Healthcare Stocks: Madrigal Pharmaceuticals (MDGL), Edgewise Therapeutics (EWTX)
Barclays Analyst forecast on CH:YDO1
Eliana Merle
Barclays
Barclays
CHF780.75
Buy
―
Assigned
05/08/26
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Barclays
Canaccord Genuity Analyst forecast on CH:YDO1
Edward Nash
Canaccord Genuity
Canaccord Genuity
CHF475.41→CHF468.12
Buy
―
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $578 from $587 at CanaccordMadrigal Pharmaceuticals price target lowered to $578 from $587 at Canaccord
Evercore ISI Analyst forecast on CH:YDO1
Michael DiFiore
Evercore ISI
Evercore ISI
CHF528.06→CHF525.63
Buy
―
Reiterated
05/07/26
Madrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISIMadrigal Pharmaceuticals price target lowered to $649 from $652 at Evercore ISI
TD Cowen Analyst forecast on CH:YDO1
Ritu Baral
TD Cowen
TD Cowen
CHF521.58
Buy
―
Reiterated
05/06/26
Analysts Offer Insights on Healthcare Companies: Madrigal Pharmaceuticals (NASDAQ: MDGL) and Pennant Group (NASDAQ: PNTG)
Clear Street Analyst forecast on CH:YDO1
Kaveri Pohlman
Clear Street
Clear Street
CHF431.68→CHF550.73
Buy
―
Reiterated
05/06/26
Madrigal Pharmaceuticals price target raised to $680 from $533 at Clear StreetMadrigal Pharmaceuticals price target raised to $680 from $533 at Clear Street
Oppenheimer Analyst forecast on CH:YDO1
Jay Olson
Oppenheimer
Oppenheimer
CHF526.44
Buy
―
Reiterated
02/09/26
Citizens JMP Analyst forecast on CH:YDO1
Jonathan Wolleben
Citizens JMP
Citizens JMP
CHF426.82→CHF603.38
Buy
―
Reiterated
01/20/26
Madrigal Pharmaceuticals price target raised to $745 from $527 at CitizensMadrigal Pharmaceuticals price target raised to $745 from $527 at Citizens
Wolfe Research Analyst forecast on CH:YDO1
Andy Chen
Wolfe Research
Wolfe Research
―
Hold
―
Downgraded
01/06/26
Madrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe ResearchMadrigal Pharmaceuticals downgraded to Peer Perform from Outperform at Wolfe Research
B. Riley Securities Analyst forecast on CH:YDO1
William Wood
B. Riley Securities
B. Riley Securities
CHF453.55→CHF542.63
Buy
―
Reiterated
12/11/25
Madrigal Pharmaceuticals price target raised to $670 from $560 at B. RileyMadrigal Pharmaceuticals price target raised to $670 from $560 at B. Riley
Cantor Fitzgerald Analyst forecast on CH:YDO1
Prakhar Agrawal
Cantor Fitzgerald
Cantor Fitzgerald
―
Buy
―
Upgraded
11/04/25
Madrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor FitzgeraldMadrigal Pharmaceuticals upgraded to Overweight from Neutral at Cantor Fitzgerald
Leerink Partners Analyst forecast on CH:YDO1
Thomas Smith
Leerink Partners
Leerink Partners
―
Buy
―
Reiterated
08/19/25
Madrigal Pharmaceuticals: Pioneering MASH Treatment with Rezdiffra's European Market Breakthrough
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Madrigal Pharmaceuticals

3 Months
Akash TewariJefferies
Success Rate
11/15 ratings generated profit
73%
Average Return
+31.49%
Copying Akash Tewari's trades and holding each position for 3 Months would result in 73.33% of your transactions generating a profit, with an average return of +31.49% per trade.
1 Year
Yasmeen RahimiPiper Sandler
Success Rate
13/15 ratings generated profit
87%
Average Return
+38.69%
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 86.67% of your transactions generating a profit, with an average return of +38.69% per trade.
2 Years
Akash TewariJefferies
Success Rate
15/15 ratings generated profit
100%
Average Return
+136.62%
Copying Akash Tewari's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +136.62% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

YDO1 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
5
4
3
2
4
Buy
15
13
8
11
10
Hold
7
6
4
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
27
23
15
15
17
In the current month, YDO1 has received 14 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. YDO1 average Analyst price target in the past 3 months is 548.09.
Each month's total comprises the sum of three months' worth of ratings.

YDO1 Financial Forecast

YDO1 Earnings Forecast

Next quarter’s earnings estimate for YDO1 is -$2.23 with a range of -$3.80 to -$1.30. The previous quarter’s EPS was -$2.63. YDO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.
Next quarter’s earnings estimate for YDO1 is -$2.23 with a range of -$3.80 to -$1.30. The previous quarter’s EPS was -$2.63. YDO1 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.

YDO1 Sales Forecast

Next quarter’s sales forecast for YDO1 is $283.30M with a range of $261.53M to $303.88M. The previous quarter’s sales results were $252.15M. YDO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.
Next quarter’s sales forecast for YDO1 is $283.30M with a range of $261.53M to $303.88M. The previous quarter’s sales results were $252.15M. YDO1 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year YDO1 has Performed in-line its overall industry.

YDO1 Stock Forecast FAQ

What is CH:YDO1’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal’s 12-month average price target is 548.09.
    What is CH:YDO1’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:YDO1, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Madrigal a Buy, Sell or Hold?
        Madrigal has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
          What is Madrigal’s share price target?
          The average share price target for Madrigal is 548.09. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is $780.75 ,and the lowest forecast is $415.96. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Madrigal?
            Madrigal’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
              How can I buy shares of Madrigal?
              To buy shares of CH:YDO1, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.